Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

Investigational New Drugs

Volumn 18, Issue 3, 2000, Pages 265-267

  Vuky, Jacqueline ^a,b   McCaffrey, John ^a   Ginsberg, Michelle ^a   Mariani, Tania ^a   Bajorin, Dean F ^a,b   Bosl, George J ^a,b   Motzer, Robert J ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Memorial Hospital   (United States)

Author keywords

Cisplatin refractory; Germ cell tumor; Pyrazoloacridine

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; LORAZEPAM; PYRAZINAMIDE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GERM CELL TUMOR; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ACRIDINES; ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; GERMINOMA; HUMANS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PYRAZOLES; TESTICULAR NEOPLASMS;

EID: 0033894907     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006434008357     Document Type: Article

References (9)

1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337: 242-253, 1997
2. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500-2504, 1998
3. McCaffrey JA, Mazurridar M, Bajorin DF, Bosi GJ, Vlamis V, Motzer RJ: Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559-2563, 1997
4. Motzer RJ: High dose chemotherapy for germ cell tumors (GCT): Memorial Sloan-Kettering Cancer Center. Bone Marrow Transplant, 18 suppl1: S53-54, 1996
5. Adjei, AA: Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs 17: 43-48, 1999
6. Jackson RC, Sebolt JS, Shillis JL, Leopold WR: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Investigation 8: 39-47, 1990
7. Sebolt JS, Scavone SV, Pinter CD, Hamelechle KL, Von Hoff DD, Jackson RC: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47: 4299-4304, 1987
8. Rowinsky EK, Noe DA, Growchow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of pyrazolacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13: 1975-1984, 1995
9. Lo Russo P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC 366140 (PD 115934). Clin Cancer Res 1: 1487-1493, 1995